Gregory Bonfiglio, Proteus Venture - Investing exclusively in Regenerative Medicine




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Gregory Bonfiglio, Proteus Venture - Investing exclusively in Regenerative Medicine
Released on: June 22, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    The RM field is expanding rapidly, and many RM companies are poised for significant increases in valuation.
  • Summary
  • Transcript
  • Participants
  • Company
The RM field is expanding rapidly, and many RM companies are poised for significant increases in valuation. Juno Therapeutics, bluebird bio, Kite Pharma and Mesoblast are examples of RM technology-based companies that have recently experienced significant appreciation and billion-dollar valuations. During the World Stem Cell and Regenerative Medicine Congress in London, Gregory Bonfiglio, Managing Partner at Proteus Ventures, talks to Adrian Dawkes about their investment strategy and explains why having'Immuno' in your company name almost guarantees a meeting with investors.
The RM field is expanding rapidly, and many RM companies are poised for significant increases in valuation. Juno Therapeutics, bluebird bio, Kite Pharma and Mesoblast are examples of RM technology-based companies that have recently experienced significant appreciation and billion-dollar valuations. During the World Stem Cell and Regenerative Medicine Congress in London, Gregory Bonfiglio, Managing Partner at Proteus Ventures, talks to Adrian Dawkes about their investment strategy and explains why having'Immuno' in your company name almost guarantees a meeting with investors.
The RM field is expanding rapidly, and many RM companies are poised for significant increases in valuation. Juno Therapeutics, bluebird bio, Kite Pharma and Mesoblast are examples of RM technology-based companies that have recently experienced significant appreciation and billion-dollar valuations. During the World Stem Cell and Regenerative Medicine Congress in London, Gregory Bonfiglio, Managing Partner at Proteus Ventures, talks to Adrian Dawkes about their investment strategy and explains why having'Immuno' in your company name almost guarantees a meeting with investors.
The RM field is expanding rapidly, and many RM companies are poised for significant increases in valuation. Juno Therapeutics, bluebird bio, Kite Pharma and Mesoblast are examples of RM technology-based companies that have recently experienced significant appreciation and billion-dollar valuations. During the World Stem Cell and Regenerative Medicine Congress in London, Gregory Bonfiglio, Managing Partner at Proteus Ventures, talks to Adrian Dawkes about their investment strategy and explains why having'Immuno' in your company name almost guarantees a meeting with investors.